The U.S. Food and Drug Administration has selected London-based Limbic as the first AI-led mental healthcare company for its new Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot program. Starting Aug. 27, its Unpacked service will provide clinician-supervised AI therapy to eligible Medicare patients with depression and anxiety.
The service delivers cognitive behavioral therapy (CBT) through scheduled telephone conversations with an AI voice agent. Licensed clinicians oversee each patient's care from beginning to end, according to a company press release.
How the pilot works
The FDA program runs alongside the Centers for Medicare & Medicaid Services' (CMS) Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model. ACCESS pays participating providers based on whether patients improve rather than how many services they receive. TEMPO will give the FDA real-world data on the technology's safety and outcomes.
This is not AI replacing a therapist, said Patricia Taylor, licensed clinical psychologist and head of Clinical Operations at Limbic, in a statement. "Unpacked is a clinical service, and a clinician remains responsible for every patient. AI allows our team to provide immediate care to far more people than traditional models."
The program's payment structure represents a shift for mental healthcare delivery. Providers are rewarded for patient outcomes, not service volume, which aligns incentives with clinical results.
What this means for providers
For healthcare organizations watching the AI for Healthcare space, this pilot offers a concrete example of how regulators are approaching AI-mediated care. The FDA's participation signals a formal pathway for evaluating AI tools in clinical settings.
The model also depends on AI Agents & Automation handling routine therapy conversations while human clinicians manage oversight. That division of labor could inform how other providers structure AI-assisted care teams.
Why this matters for healthcare professionals
Clinicians should watch how the FDA defines safety and effectiveness for AI-delivered therapy in this pilot. The outcome-based payment model could reshape how mental health services are reimbursed if it proves successful. For now, the program applies to a specific Medicare population, but the regulatory and payment frameworks being tested here may influence broader adoption.
Your membership also unlocks:
